Company intelligence / Profile preview

Ergosol

Ownership: Private
Employees: ~1800
Development stage: Other

Overview

Ergomed is an international specialist in clinical development and pharmacovigilance with particular expertise in oncology and rare diseases. It manages trials across all phases and has built a portfolio of co-development partnerships with pharma/biotech companies. Its own pipeline includes several partnered or supported assets at various stages up to NDA/BLA approval.

Therapeutic areas: OncologyWomen's HealthRare DiseasesImmunologyHematologyNeurologyInfectious Diseases
Modalities: Synthetic peptidePeptide-based blood coagulantSmall molecule (inferred from typical CRO activities)Biologic (inferred from typical CRO activities)
Industry: Contract Research Organization

Partnerships

Numerous pharma and biotech clients globally through both fee-for-service contracts and risk-sharing/co-development deals; specific partners not disclosed by name in available sources.

Beyond the preview

Go deeper on Ergosol.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ergosol.

Explore the full profile